Trending Topic

Motor neuron synapses with muscle fiber via electrical impulse transmission and neurotransmitter release, forming neuromuscular junctions , motor neuron, neuroscience
15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a terminal condition with a typical life expectancy of 2–5 years from symptom onset. […]

Search Results

Showing Results for safety

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode of Visionary Voices, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, joins us to explore how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care.

Mark CompleteCompleted
BookmarkBookmarked

Broadest approval to date in generalized myasthenia gravis The FDA approval of nipocalimab for generalized myasthenia gravis (gMG) introduces a targeted therapy within a validated class, offering the potential for durable disease control across the broadest patient population to date. ...

Mark CompleteCompleted
BookmarkBookmarked

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...

Mark CompleteCompleted
BookmarkBookmarked

In this Q&A, Dr Andy Liu, Associate Professor of Neurology at Duke University School of Medicine, discusses his presentation on the clinical use of lecanemab in Alzheimer’s disease. Drawing on real-world experience and findings from the 2022 CLARITY AD study, Dr Liu explores the treatment’s benefits, challenges in daily practice and the importance of patient-centred care in this evolving therapeutic landscape.

Mark CompleteCompleted
BookmarkBookmarked
Pavel Burko, Ilias Miltiadis, Mahsa Alavi

Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...

Mark CompleteCompleted
BookmarkBookmarked

The 2025 Annual Meeting of the American Academy of Neurology in San Diego brought together over 14,500 neurology professionals from 110 countries and all 50 US states, alongside more than 300 exhibiting companies. It was a week filled with inspiring science, learning, and global collaboration—all in support of advancing brain health for all. Among the many highlights were the late-breaking abstracts, showcasing some of the most exciting developments in neurology. From this impressive selection, we’ve chosen five standout presentations that reflect the innovation and momentum seen throughout the meeting.

Mark CompleteCompleted
BookmarkBookmarked

The FDA has approved tenecteplase (TNKase) for the treatment of acute ischemic stroke (AIS) in adults, marking the first new stroke-specific thrombolytic approval in nearly three decades. Administered as a single five-second intravenous bolus, tenecteplase allows for faster administration compared to the current standard of care alteplase, which is administered as a bolus-plus-infusion regimen.

Mark CompleteCompleted
BookmarkBookmarked

The first prenatal treatment for spinal muscular atrophy showed promise in a single case report.

Mark CompleteCompleted
BookmarkBookmarked

Seizures are one of the most frequent neurological disorders in neonates − the incidence of seizures in infants born at term is 1–3 per 1,000 live births, and is even higher in both preterm and very-low-birth-weight infants at 1–13 per 1,000 live births.1 Seizures may ...

Mark CompleteCompleted
BookmarkBookmarked

The Food and Drug Administration (FDA) has approved ONAPGO™ (apomorphine hydrochloride) sublingual film for the treatment of “off” episodes in Parkinson’s disease (PD), providing patients with a new, on-demand therapy to rapidly alleviate motor symptoms when standard medications wear off.

Mark CompleteCompleted
BookmarkBookmarked

Rotterdam (ka). ‘Towards a better headache treatment for everyone’ - The ambitious motto of achieving better headache treatment for everyone was at the centre of the 18th European Headache Congress in Rotterdam. The top-class conference is regarded as an international platform for scientific exchange on the subject of headaches. Confidently chaired by Prof Antoinette Maassen van den Brink, Rotterdam and Prof Jan Versijpt, Brussels, the EHC 2024 Congress was a complete success with around 2,200 participants.

Mark CompleteCompleted
BookmarkBookmarked

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare, autoimmune neurological disorder in which peripheral nerve demyelination typically results in weakness, impaired limb sensation, fatigue and pain.1–4 CIDP may adversely affect activities of daily living, with a substantial impact on functional ...

Mark CompleteCompleted
BookmarkBookmarked

The phase 3b SMART study has shown that 83% of paediatric patients with spinal muscular atrophy (SMA) weighing between 8.5 and 21 kg achieved significant motor improvements following treatment with intravenous onasemnogene abeparvovec in a recent article published in Neurology.

Mark CompleteCompleted
BookmarkBookmarked
Joseph Samaha, Jim Dagher, Shayan Abdollah Zadegan

Huntington’s disease (HD) is a neurodegenerative disease inherited in an autosomal dominant manner. It is caused by an expansion of cytosine, adenine, guanine (CAG) repeats within the huntingtin (HTT) gene, which is located on chromosome 4. This pathological expansion of ...

Mark CompleteCompleted
BookmarkBookmarked

A new study has revealed that early treatment with ocrelizumab significantly reduces disease activity and long-term progression in patients with early-stage relapsing-remitting multiple sclerosis (RRMS).

Load More...
Close Popup